Nutrition Metabolism and Cardiovascular Diseases最新文献_第10页

Dietary tryptophan intake density and the risk of cardiovascular diseases: insights from a prospective cohort study 膳食色氨酸摄入密度与心血管疾病风险：来自前瞻性队列研究的见解

IF 3.7 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Nutrition Metabolism and Cardiovascular Diseases

Pub Date : 2025-11-20 DOI: 10.1016/j.numecd.2025.104468

Hieu Lan Nguyen , Linh Thuy Le , Thinh Gia Nguyen , Quynh Thu Nguyen , Hieu Van Nguyen , Ngoan Tran Le

Background and aim

Tryptophan's metabolic products, serotonin and melatonin, exhibit antioxidant activity and neuroprotective properties, thereby preventing mortality from cardiovascular diseases (CVD). We aim to examine the relationship between dietary tryptophan intake density and the risk of CVD.

Methods and results

A prospective cohort study was conducted in northern Vietnam from 2008 to 2019, which comprises 42,146 participants aged 10 and older. Dietary tryptophan intake density per 1000 kcal was assessed using a validated semi-quantitative food frequency questionnaire. CVD deaths were 348 cases. The mean age was 38.5 years; 48 % were male and 52 % were female. The median follow-up duration was 11.01 years. Hazard ratio and 95 % confidence interval HR (95 % CI) were calculated for the association between dietary tryptophan intake density and mortality risks from CVD.

The inverse association between dietary tryptophan intake density, top to bottom quintile, and CVD was seen for the entire study population, HR (95 % CI): 0.59 (0.42, 0.83), and after excluding deaths in the first three years, HR (95 % CI): 0.59 (0.41, 0.86). The results remained after additional adjustment for pack-years of smoking. A similar protective pattern was observed in subgroups with BMI <23 kg/m², smokers, drinkers, and men. The beneficial effect was observed in both young adults and those 65 years or older.

Conclusions

A beneficial effect of dietary tryptophan intake density against the risk of CVD was observed. The findings warrant further research to understand the mechanism and its application in preventing CVD.

背景和目的：色氨酸的代谢产物血清素和褪黑素具有抗氧化活性和神经保护特性，从而预防心血管疾病（CVD）的死亡。我们的目的是研究膳食色氨酸摄入密度与心血管疾病风险之间的关系。方法与结果：2008年至2019年，在越南北部进行了一项前瞻性队列研究，其中包括42,146名10岁及以上的参与者。使用经过验证的半定量食物频率问卷评估每1000千卡的膳食色氨酸摄入密度。心血管疾病死亡348例。平均年龄38.5岁；其中48%为男性，52%为女性。中位随访时间为11.01年。计算膳食色氨酸摄入密度与心血管疾病死亡风险之间的风险比和95%置信区间HR （95% CI）。在整个研究人群中，膳食色氨酸摄入密度、从上到下五分位数与心血管疾病呈负相关，相对危险度（95% CI）： 0.59(0.42, 0.83)，在排除前三年的死亡后，相对危险度（95% CI）： 0.59（0.41, 0.86）。在对吸烟包年进行额外调整后，结果仍然存在。在BMI为2的亚组、吸烟者、饮酒者和男性中也观察到类似的保护模式。在年轻人和65岁以上的老年人中都观察到有益的效果。结论：观察到膳食色氨酸摄入密度对心血管疾病风险的有益影响。这些发现值得进一步研究，以了解其机制及其在预防心血管疾病中的应用。

{"title":"Dietary tryptophan intake density and the risk of cardiovascular diseases: insights from a prospective cohort study","authors":"Hieu Lan Nguyen , Linh Thuy Le , Thinh Gia Nguyen , Quynh Thu Nguyen , Hieu Van Nguyen , Ngoan Tran Le","doi":"10.1016/j.numecd.2025.104468","DOIUrl":"10.1016/j.numecd.2025.104468","url":null,"abstract":"<div><h3>Background and aim</h3><div>Tryptophan's metabolic products, serotonin and melatonin, exhibit antioxidant activity and neuroprotective properties, thereby preventing mortality from cardiovascular diseases (CVD). We aim to examine the relationship between dietary tryptophan intake density and the risk of CVD.</div></div><div><h3>Methods and results</h3><div>A prospective cohort study was conducted in northern Vietnam from 2008 to 2019, which comprises 42,146 participants aged 10 and older. Dietary tryptophan intake density per 1000 kcal was assessed using a validated semi-quantitative food frequency questionnaire. CVD deaths were 348 cases. The mean age was 38.5 years; 48 % were male and 52 % were female. The median follow-up duration was 11.01 years. Hazard ratio and 95 % confidence interval HR (95 % CI) were calculated for the association between dietary tryptophan intake density and mortality risks from CVD.</div><div>The inverse association between dietary tryptophan intake density, top to bottom quintile, and CVD was seen for the entire study population, HR (95 % CI): 0.59 (0.42, 0.83), and after excluding deaths in the first three years, HR (95 % CI): 0.59 (0.41, 0.86). The results remained after additional adjustment for pack-years of smoking. A similar protective pattern was observed in subgroups with BMI <23 kg/m<sup>2</sup>, smokers, drinkers, and men. The beneficial effect was observed in both young adults and those 65 years or older.</div></div><div><h3>Conclusions</h3><div>A beneficial effect of dietary tryptophan intake density against the risk of CVD was observed. The findings warrant further research to understand the mechanism and its application in preventing CVD.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"36 3","pages":"Article 104468"},"PeriodicalIF":3.7,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex specific responses to oral vs. subcutaneous semaglutide in type 2 diabetes mellitus: A 12-month real-world study 口服西马鲁肽与皮下注射西马鲁肽治疗2型糖尿病的性别特异性反应：一项为期12个月的真实世界研究

IF 3.7 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Nutrition Metabolism and Cardiovascular Diseases

Pub Date : 2025-11-15 DOI: 10.1016/j.numecd.2025.104462

Alessandra Piccione , Maria Bonsangue , Martina Barone , Enrica Vigneri , Mariagrazia Irene Mineo , Laura Tomasello , Laura Maniscalco , Felicia Pantò , Giorgio Arnaldi , Valentina Guarnotta

Background and aim

Semaglutide therapy improves glycaemic control, weight loss, and cardiovascular risk reduction in patients with type 2 diabetes mellitus (T2D). Sex-specific differences in the response to oral versus subcutaneous formulation remain unexplored in real-world settings. This interventional pilot study compares the 12-month effectiveness of oral and subcutaneous semaglutide in a real-world cohort of T2D patients, with focus to sex-based differences in treatment outcomes.

Methods and results

Two-hundred and twelve T2D patients, equally assigned to oral or subcutaneous semaglutide (n = 106 per group), were enrolled. The primary endpoint was the change in HbA1c. Secondary endpoints included variations in anthropometric and metabolic parameters, analysed both in the overall cohort and through a sex-stratified approach. Two-hundred and eight patients completed the study. In men, subcutaneous semaglutide resulted in significant reductions in delta(Δ)_weight (p = 0.010), Δ_HbA1c (p = 0.037), and Δ_LDL (p = 0.038) compared to the oral formulation. In women, subcutaneous semaglutide led to significantly lower Δ_hepatic steatosis index (p = 0.024). Additionally, women treated with subcutaneous semaglutide showed a significantly greater reduction in Δ_GOT (p = 0.035) compared to men.

Conclusions

This real-world study suggests that subcutaneous semaglutide provides greater metabolic benefits than the oral formulation, particularly in men. Women treated with subcutaneous semaglutide experience more favorable liver responses, emphasizing the personalization of T2D treatment.

背景和目的：西马鲁肽治疗可改善2型糖尿病（T2D）患者的血糖控制、体重减轻和心血管风险降低。对口服和皮下制剂的反应的性别特异性差异仍未在现实环境中探索。这项介入性的初步研究比较了口服和皮下塞马鲁肽在现实世界T2D患者队列中12个月的有效性，重点是基于性别的治疗结果差异。方法和结果：纳入了212例T2D患者，平均分配给口服或皮下注射西马鲁肽（每组106例）。主要终点是HbA1c的变化。次要终点包括人体测量和代谢参数的变化，通过总体队列和性别分层方法进行分析。208名患者完成了这项研究。在男性中，与口服制剂相比，皮下注射semaglutide可显著降低delta（Δ）_weight （p = 0.010）、Δ_HbA1c （p = 0.037）和Δ_LDL （p = 0.038）。在女性中，皮下注射semaglutide可显著降低Δ_hepatic脂肪变性指数（p = 0.024）。此外，接受皮下塞马鲁肽治疗的女性与男性相比，Δ_GOT的降低幅度更大（p = 0.035）。结论：这项现实世界的研究表明，皮下注射semaglutide比口服制剂提供更大的代谢益处，特别是在男性中。接受皮下西马鲁肽治疗的女性有更有利的肝脏反应，强调了T2D治疗的个体化。

{"title":"Sex specific responses to oral vs. subcutaneous semaglutide in type 2 diabetes mellitus: A 12-month real-world study","authors":"Alessandra Piccione , Maria Bonsangue , Martina Barone , Enrica Vigneri , Mariagrazia Irene Mineo , Laura Tomasello , Laura Maniscalco , Felicia Pantò , Giorgio Arnaldi , Valentina Guarnotta","doi":"10.1016/j.numecd.2025.104462","DOIUrl":"10.1016/j.numecd.2025.104462","url":null,"abstract":"<div><h3>Background and aim</h3><div>Semaglutide therapy improves glycaemic control, weight loss, and cardiovascular risk reduction in patients with type 2 diabetes mellitus (T2D). Sex-specific differences in the response to oral versus subcutaneous formulation remain unexplored in real-world settings. This interventional pilot study compares the 12-month effectiveness of oral and subcutaneous semaglutide in a real-world cohort of T2D patients, with focus to sex-based differences in treatment outcomes.</div></div><div><h3>Methods and results</h3><div>Two-hundred and twelve T2D patients, equally assigned to oral or subcutaneous semaglutide (n = 106 per group), were enrolled. The primary endpoint was the change in HbA1c. Secondary endpoints included variations in anthropometric and metabolic parameters, analysed both in the overall cohort and through a sex-stratified approach. Two-hundred and eight patients completed the study. In men, subcutaneous semaglutide resulted in significant reductions in delta(Δ)_weight (p = 0.010), Δ_HbA1c (p = 0.037), and Δ_LDL (p = 0.038) compared to the oral formulation. In women, subcutaneous semaglutide led to significantly lower Δ_hepatic steatosis index (p = 0.024). Additionally, women treated with subcutaneous semaglutide showed a significantly greater reduction in Δ_GOT (p = 0.035) compared to men.</div></div><div><h3>Conclusions</h3><div>This real-world study suggests that subcutaneous semaglutide provides greater metabolic benefits than the oral formulation, particularly in men. Women treated with subcutaneous semaglutide experience more favorable liver responses, emphasizing the personalization of T2D treatment.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"36 3","pages":"Article 104462"},"PeriodicalIF":3.7,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145879250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gut microbiota profiles by LDL-C target achievement in statin-treated patients: A cross-sectional study 他汀类药物治疗患者LDL-C目标实现的肠道微生物群概况：一项横断面研究。

IF 3.7 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Nutrition Metabolism and Cardiovascular Diseases

Pub Date : 2025-11-15 DOI: 10.1016/j.numecd.2025.104465

Yi-Hsueh Liu , Po Peng , Wei-Chun Hung , Ping-Hsun Wu , Cheng-Yuan Kao , Pei-Yu Wu , Jiun-Chi Huang , Szu-Chia Chen , Chao-Hung Kuo

Background and aims

Hyperlipidemia is linked to gut microbiota alterations, but the impact of statins on the gut microbiome remains unclear, especially concerning different low-density lipoprotein cholesterol (LDL-C) targets. This study explores gut microbiome changes in chronic disease patients under varying LDL-C targets with statin therapy.

Methods and results

A total of 125 patients (77 males and 48 females) diagnosed with chronic diseases, specifically diabetes mellitus (87 %), hypertension (74 %), and chronic kidney disease (48 %), were recruited. Fecal samples were collected from the participants to analyze the composition of the gut microbiota using Illumina sequencing of the 16S ribosomal ribonucleic acid gene. The patients were divided into two groups according to LDL-C level, including 57 patients in the LDL-C target–achieved group (LDL-C < 70 mg/dL), and 68 in the LDL-C target–not-achieved group (LDL-C ≥ 70 mg/dL). There were no significant differences in microbial species diversity (Chao1 index and Shannon index), beta diversity and microbial dysbiosis index between the two groups. However, a distinct microbial community structure was found in the LDL-C target–achieved group, with decreased abundances at the genus level of Barnesiella, Coprococcus 1, Flavonifractor, Odoribacter and Coprobacter.

Conclusion

No significant difference in alpha diversity, beta diversity, and microbial dysbiosis index were found between the LDL-C target–achieved and target–not-achieved groups. However, the LDL-C target–achieved group was associated with a significant reduction in short-chain fatty acid-producing bacteria, including taxa Barnesiella, Coprococcus 1, Flavonifractor and Odoribacter.

背景和目的：高脂血症与肠道微生物群改变有关，但他汀类药物对肠道微生物群的影响尚不清楚，特别是不同的低密度脂蛋白胆固醇（LDL-C）靶点。本研究探讨了慢性疾病患者在接受他汀类药物治疗时不同LDL-C靶点下肠道微生物组的变化。方法与结果：共纳入125例诊断为慢性疾病的患者（男性77例，女性48例），其中糖尿病（87%）、高血压（74%）和慢性肾病（48%）。收集参与者的粪便样本，使用Illumina 16S核糖体核糖核酸基因测序分析肠道微生物群的组成。根据LDL-C水平将患者分为两组，其中LDL-C达标组57例（LDL-C）结论：LDL-C达标组与未达标组在α多样性、β多样性、微生物生态失调指数上均无显著差异。然而，LDL-C达标组与产生短链脂肪酸的细菌显著减少有关，包括巴氏菌、Coprococcus 1、黄酮因子和臭杆菌。

{"title":"Gut microbiota profiles by LDL-C target achievement in statin-treated patients: A cross-sectional study","authors":"Yi-Hsueh Liu , Po Peng , Wei-Chun Hung , Ping-Hsun Wu , Cheng-Yuan Kao , Pei-Yu Wu , Jiun-Chi Huang , Szu-Chia Chen , Chao-Hung Kuo","doi":"10.1016/j.numecd.2025.104465","DOIUrl":"10.1016/j.numecd.2025.104465","url":null,"abstract":"<div><h3>Background and aims</h3><div>Hyperlipidemia is linked to gut microbiota alterations, but the impact of statins on the gut microbiome remains unclear, especially concerning different low-density lipoprotein cholesterol (LDL-C) targets. This study explores gut microbiome changes in chronic disease patients under varying LDL-C targets with statin therapy.</div></div><div><h3>Methods and results</h3><div>A total of 125 patients (77 males and 48 females) diagnosed with chronic diseases, specifically diabetes mellitus (87 %), hypertension (74 %), and chronic kidney disease (48 %), were recruited. Fecal samples were collected from the participants to analyze the composition of the gut microbiota using Illumina sequencing of the 16S ribosomal ribonucleic acid gene. The patients were divided into two groups according to LDL-C level, including 57 patients in the LDL-C target–achieved group (LDL-C < 70 mg/dL), and 68 in the LDL-C target–not-achieved group (LDL-C ≥ 70 mg/dL). There were no significant differences in microbial species diversity (Chao1 index and Shannon index), beta diversity and microbial dysbiosis index between the two groups. However, a distinct microbial community structure was found in the LDL-C target–achieved group, with decreased abundances at the genus level of <em>Barnesiella</em>, <em>Coprococcus 1</em>, <em>Flavonifractor</em>, <em>Odoribacter</em> and <em>Coprobacter</em>.</div></div><div><h3>Conclusion</h3><div>No significant difference in alpha diversity, beta diversity, and microbial dysbiosis index were found between the LDL-C target–achieved and target–not-achieved groups. However, the LDL-C target–achieved group was associated with a significant reduction in short-chain fatty acid-producing bacteria, including taxa <em>Barnesiella</em>, <em>Coprococcus 1</em>, <em>Flavonifractor</em> and <em>Odoribacter</em>.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"36 3","pages":"Article 104465"},"PeriodicalIF":3.7,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145879191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of trajectories of sex-specific quintiles of predicted lean mass and risk of cardiovascular disease: a prospective cohort study 预测瘦体重的性别特异性五分位数轨迹与心血管疾病风险的关联：一项前瞻性队列研究

IF 3.7 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Nutrition Metabolism and Cardiovascular Diseases

Pub Date : 2025-11-14 DOI: 10.1016/j.numecd.2025.104467

Qian Liu , Haozhe Cui , Yuntao Wu

Background and aim

Although indicators such as body mass index, waist circumference, and waist-to-hip ratio can predict the risk of cardiovascular diseases (CVDs), these measures do not adequately reflect body composition, particularly lean mass, which plays a crucial role in metabolic health. Evidence regarding the longitudinal relationship between lean mass and the risk of CVDs remains limited. Therefore, this study aimed to investigate the association between trajectories of sex-specific quintiles of predicted lean mass and the subsequent risk of developing CVDs.

Methods and results

The participants were drawn from the Kailuan study, which is an ongoing prospective cohort study. The trajectories of sex-specific quintiles of predicted lean mass from 2006/2008 survey to 2010/2011 survey were identified by group-based trajectory modeling. The association between predicted lean mass and the risk of CVDs was assessed using Cox proportional hazards models (hazard ratio [HR], 95 %confidence interval [CI]). A total of 43,299 participants were included in the study and divided into 5 groups according to predicted lean mass trajectories (low-stable group, low-increasing group, moderate-decreasing group, moderate-increasing group, and high-stable group). During a median follow-up of 10.03 years, a total of 3413 participants developed CVDs. After adjustment for covariates, compared with the low-stable group, lower risks of CVDs were observed in the low-increasing group (HR: 0.89; 95 %CI: 0.81–0.99), the moderate-increasing group (HR: 0.82; 95 %CI: 0.74–0.92), and the high-stable group (HR: 0.81; 95 %CI: 0.71–0.91).

Conclusions

The trajectories of sex-specific quintiles of predicted lean mass, especially long-term high predicted lean body mass, may be associated with a reduced risk of CVDs.

背景与目的：虽然身体质量指数、腰围和腰臀比等指标可以预测心血管疾病（cvd）的风险，但这些指标并不能充分反映身体组成，尤其是瘦体重，而瘦体重在代谢健康中起着至关重要的作用。关于瘦体重和心血管疾病风险之间的纵向关系的证据仍然有限。因此，本研究旨在探讨预测瘦质量的性别特异性五分位数轨迹与随后发生心血管疾病的风险之间的关系。方法和结果：参与者来自开滦研究，这是一项正在进行的前瞻性队列研究。通过分组轨迹模型确定了2006/2008年至2010/2011年期间预测瘦质量的性别分位数轨迹。使用Cox比例风险模型（风险比[HR]， 95%置信区间[CI]）评估预测瘦体重与心血管疾病风险之间的关系。研究共纳入43299名参与者，根据预测瘦质量轨迹分为5组（低稳定组、低增加组、中减少组、中增加组和高稳定组）。在中位10.03年的随访期间，共有3413名参与者患上了心血管疾病。调整协变量后，与低稳定组相比，低升高组（HR: 0.89, 95% CI: 0.81-0.99）、中升高组（HR: 0.82, 95% CI: 0.74-0.92）和高稳定组（HR: 0.81, 95% CI: 0.71-0.91）的心血管疾病风险较低。结论：预测瘦体重的性别特异性五分位数的轨迹，特别是长期高预测瘦体重，可能与心血管疾病风险降低有关。

{"title":"Association of trajectories of sex-specific quintiles of predicted lean mass and risk of cardiovascular disease: a prospective cohort study","authors":"Qian Liu , Haozhe Cui , Yuntao Wu","doi":"10.1016/j.numecd.2025.104467","DOIUrl":"10.1016/j.numecd.2025.104467","url":null,"abstract":"<div><h3>Background and aim</h3><div>Although indicators such as body mass index, waist circumference, and waist-to-hip ratio can predict the risk of cardiovascular diseases (CVDs), these measures do not adequately reflect body composition, particularly lean mass, which plays a crucial role in metabolic health. Evidence regarding the longitudinal relationship between lean mass and the risk of CVDs remains limited. Therefore, this study aimed to investigate the association between trajectories of sex-specific quintiles of predicted lean mass and the subsequent risk of developing CVDs.</div></div><div><h3>Methods and results</h3><div>The participants were drawn from the Kailuan study, which is an ongoing prospective cohort study. The trajectories of sex-specific quintiles of predicted lean mass from 2006/2008 survey to 2010/2011 survey were identified by group-based trajectory modeling. The association between predicted lean mass and the risk of CVDs was assessed using Cox proportional hazards models (hazard ratio [HR], 95 %confidence interval [CI]). A total of 43,299 participants were included in the study and divided into 5 groups according to predicted lean mass trajectories (low-stable group, low-increasing group, moderate-decreasing group, moderate-increasing group, and high-stable group). During a median follow-up of 10.03 years, a total of 3413 participants developed CVDs. After adjustment for covariates, compared with the low-stable group, lower risks of CVDs were observed in the low-increasing group (HR: 0.89; 95 %CI: 0.81–0.99), the moderate-increasing group (HR: 0.82; 95 %CI: 0.74–0.92), and the high-stable group (HR: 0.81; 95 %CI: 0.71–0.91).</div></div><div><h3>Conclusions</h3><div>The trajectories of sex-specific quintiles of predicted lean mass, especially long-term high predicted lean body mass, may be associated with a reduced risk of CVDs.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"36 3","pages":"Article 104467"},"PeriodicalIF":3.7,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145776333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Healthy sleep habits as part of the Mediterranean diet pyramid 健康的睡眠习惯是地中海饮食金字塔的一部分。

IF 3.7 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Nutrition Metabolism and Cardiovascular Diseases

Pub Date : 2025-11-14 DOI: 10.1016/j.numecd.2025.104466

Maria Fernanda Naufel , Luciano Ferreira Drager

引用次数: 0

Chinese visceral adiposity index as stronger predictor of hypertension and prehypertension in middle-aged and elderly Chinese adults: A comparative analysis with conventional adiposity indices. 中国内脏脂肪指数作为中国中老年人高血压和高血压前期的更强预测指标：与传统脂肪指数的比较分析

IF 3.7 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Nutrition Metabolism and Cardiovascular Diseases

Pub Date : 2025-11-14 DOI: 10.1016/j.numecd.2025.104471

Zhenzhen Qin, Jie Wu, Qing Ye, Shengxiang Qi, Yijia Chen, Chenchen Wang, Xin Hong

Background and aims: This study explored the link between the Chinese visceral adiposity index (CVAI) and hypertension/prehypertension in middle-aged and elderly Chinese adults, comparing its predictive accuracy with other adiposity indices.

Methods and results: Data from Nanjing's 2017-2018 chronic disease surveillance was analyzed for individuals over 45, using a generalized linear mixed model and ROC curves to assess the impact of CVAI and other indices. After adjusting for selected covariates, the results showed that, with the lowest group as the reference, the ORs of risk of hypertension were 1.536, 2.088 and 3.391 for CVAI; 1.338, 1.845 and 2.489 for the lipid accumulation product index (LAP); 1.277, 1.465 and 1.935 for the triglyceride glucose index (TyG); 1.396, 2.287, and 3.617 for body mass index (BMI); 1.961 for waist circumference (WC); 1.915 for the waist-to-height ratio (WHtR); and 1.299 for the waist-to-hip ratio (WHR), respectively. Similar results were also found in the impact of various obesity variables on prehypertension, respectively. ROC analyses indicated CVAI as the strongest predictor of hypertension and prehypertension compared to other adiposity indices.

Conclusions: CVAI is significantly associated with hypertension and prehypertension, surpassing conventional indices in predictive power for these conditions in the studied demographic.

背景与目的：本研究探讨中国中老年人内脏脂肪指数（CVAI）与高血压/高血压前期的关系，并比较其与其他肥胖指数的预测准确性。方法与结果：对南京市2017-2018年45岁以上人群慢性疾病监测数据进行分析，采用广义线性混合模型和ROC曲线评估CVAI等指标的影响。对所选协变量进行调整后，结果显示，以最低组为参照，CVAI高血压风险的or值分别为1.536、2.088和3.391；脂质堆积积指数（LAP）分别为1.338、1.845和2.489；甘油三酯葡萄糖指数（TyG）分别为1.277、1.465、1.935；体重指数（BMI）分别为1.396、2.287、3.617；腰围（WC） 1.961；腰高比（WHtR） 1.915；腰臀比（WHR）分别为1.299。在各种肥胖变量对高血压前期的影响中也分别发现了类似的结果。ROC分析表明，与其他肥胖指标相比，CVAI是高血压和高血压前期的最强预测因子。结论：CVAI与高血压和高血压前期显著相关，在预测这些疾病方面优于传统指标。

{"title":"Chinese visceral adiposity index as stronger predictor of hypertension and prehypertension in middle-aged and elderly Chinese adults: A comparative analysis with conventional adiposity indices.","authors":"Zhenzhen Qin, Jie Wu, Qing Ye, Shengxiang Qi, Yijia Chen, Chenchen Wang, Xin Hong","doi":"10.1016/j.numecd.2025.104471","DOIUrl":"https://doi.org/10.1016/j.numecd.2025.104471","url":null,"abstract":"<p><strong>Background and aims: </strong>This study explored the link between the Chinese visceral adiposity index (CVAI) and hypertension/prehypertension in middle-aged and elderly Chinese adults, comparing its predictive accuracy with other adiposity indices.</p><p><strong>Methods and results: </strong>Data from Nanjing's 2017-2018 chronic disease surveillance was analyzed for individuals over 45, using a generalized linear mixed model and ROC curves to assess the impact of CVAI and other indices. After adjusting for selected covariates, the results showed that, with the lowest group as the reference, the ORs of risk of hypertension were 1.536, 2.088 and 3.391 for CVAI; 1.338, 1.845 and 2.489 for the lipid accumulation product index (LAP); 1.277, 1.465 and 1.935 for the triglyceride glucose index (TyG); 1.396, 2.287, and 3.617 for body mass index (BMI); 1.961 for waist circumference (WC); 1.915 for the waist-to-height ratio (WHtR); and 1.299 for the waist-to-hip ratio (WHR), respectively. Similar results were also found in the impact of various obesity variables on prehypertension, respectively. ROC analyses indicated CVAI as the strongest predictor of hypertension and prehypertension compared to other adiposity indices.</p><p><strong>Conclusions: </strong>CVAI is significantly associated with hypertension and prehypertension, surpassing conventional indices in predictive power for these conditions in the studied demographic.</p>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":" ","pages":"104471"},"PeriodicalIF":3.7,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improved HDL, LDL and total cholesterol levels following a 3-month administration of Mentha spicata leaf extract and Amaranthus caudatus seed flour extracts, flavonoids and B vitamins. A placebo-controlled, double-blind, randomized clinical trial 改善高密度脂蛋白、低密度脂蛋白和总胆固醇水平，服用3个月的薄荷叶提取物和苋籽面粉提取物、类黄酮和B族维生素。一项安慰剂对照、双盲、随机临床试验。

IF 3.7 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Nutrition Metabolism and Cardiovascular Diseases

Pub Date : 2025-11-14 DOI: 10.1016/j.numecd.2025.104470

Alessandro Di Minno , Maria Vittoria Morone , Marcello Cordara , Daniele Giuseppe Buccato , Lorenza Francesca De Lellis , Hammad Ullah , Roberto Piccinocchi , Danaé S. Larsen , Alessandra Baldi , Gaetano Piccinocchi , Xiang Xiao , Roberto Sacchi , Maria Daglia

Background and aims

We have evaluated the efficacy and tolerability of two food supplements (FS) containing flavonoids (naringin and hesperidin); same doses of B3, B6, B9 and B12 vitamins, and two different doses of a blend of Mentha spicata leaf extract and Amaranthus caudatus seed flour, in subjects with borderline high total (TC) and low-density lipoprotein cholesterol (LDL-C) levels.

Methods and results

114 Participants (18–70 years) with TC levels 200–239 mg/dL, (5.18–6.19 mmol/L) and LDL-C (<159 mg/dL) were randomised into three groups to receive for 90 days the lowest (n = 38, Treatment A), the highest dose of the FS (n = 38 – Treatment B), or placebo (n = 38). Treatment B was associated with a significant reduction in LDL-C (∼31.5 mg/dL;-22%) and TC (∼19.5 mg/dL; -9%), along with an increase in high-density lipoprotein cholesterol (HDL-C). The greater efficacy of Treatment B containing the highest dose of vegetable extracts is likely attributable to its higher M. spicata extract content, as judged by high-resolution mass spectrometry analysis of the preparation.

Conclusion

The combination of different FS ingredients with different mechanisms of action can be a valuable strategy for improving lipid profiles in subjects with borderline high TC and LDL-C levels.

背景和目的：我们评估了两种含黄酮类化合物（柚皮苷和橙皮苷）的食品补充剂（FS）的疗效和耐受性；相同剂量的B3、B6、B9和B12维生素，以及两种不同剂量的薄荷叶提取物和苋籽粉的混合物，用于总脂蛋白胆固醇（TC）和低密度脂蛋白胆固醇（LDL-C）水平处于边缘的受试者。方法与结果：114例患者（18-70岁），TC水平200-239 mg/dL，（5.18-6.19 mmol/L）和LDL-C(结论：不同作用机制的FS成分联合使用可能是改善边缘高TC和LDL-C水平受试者血脂的有价值的策略。

{"title":"Improved HDL, LDL and total cholesterol levels following a 3-month administration of Mentha spicata leaf extract and Amaranthus caudatus seed flour extracts, flavonoids and B vitamins. A placebo-controlled, double-blind, randomized clinical trial","authors":"Alessandro Di Minno , Maria Vittoria Morone , Marcello Cordara , Daniele Giuseppe Buccato , Lorenza Francesca De Lellis , Hammad Ullah , Roberto Piccinocchi , Danaé S. Larsen , Alessandra Baldi , Gaetano Piccinocchi , Xiang Xiao , Roberto Sacchi , Maria Daglia","doi":"10.1016/j.numecd.2025.104470","DOIUrl":"10.1016/j.numecd.2025.104470","url":null,"abstract":"<div><h3>Background and aims</h3><div>We have evaluated the efficacy and tolerability of two food supplements (FS) containing flavonoids (naringin and hesperidin); same doses of B3, B6, B9 and B12 vitamins, and two different doses of a blend of <em>Mentha spicata</em> leaf extract and <em>Amaranthus caudatus</em> seed flour, in subjects with borderline high total (TC) and low-density lipoprotein cholesterol (LDL-C) levels.</div></div><div><h3>Methods and results</h3><div>114 Participants (18–70 years) with TC levels 200–239 mg/dL, (5.18–6.19 mmol/L) and LDL-C (<159 mg/dL) were randomised into three groups to receive for 90 days the lowest (n = 38, Treatment A), the highest dose of the FS (n = 38 – Treatment B), or placebo (n = 38). Treatment B was associated with a significant reduction in LDL-C (∼31.5 mg/dL;-22%) and TC (∼19.5 mg/dL; -9%), along with an increase in high-density lipoprotein cholesterol (HDL-C). The greater efficacy of Treatment B containing the highest dose of vegetable extracts is likely attributable to its higher <em>M. spicata</em> extract content, as judged by high-resolution mass spectrometry analysis of the preparation.</div></div><div><h3>Conclusion</h3><div>The combination of different FS ingredients with different mechanisms of action can be a valuable strategy for improving lipid profiles in subjects with borderline high TC and LDL-C levels.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"36 3","pages":"Article 104470"},"PeriodicalIF":3.7,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145949357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between estimated glucose disposal rate and incidence of cardiovascular diseases in a population with cardiovascular-kidney-metabolic syndrome stages 0–3: A large prospective cohort study 在心血管-肾-代谢综合征0-3期人群中，估计葡萄糖处置率与心血管疾病发病率之间的关系：一项大型前瞻性队列研究

IF 3.7 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Nutrition Metabolism and Cardiovascular Diseases

Pub Date : 2025-11-14 DOI: 10.1016/j.numecd.2025.104469

Yaohua Hu, Xinyang Li, Jian Li, Mengyuan Yu, Xu Li, Wenpeng Cui

Background and aim

There is growing interest in the intricate relationships among metabolic processes, renal health, and cardiovascular disease (CVD). Individuals in the early stages of Cardiovascular-Kidney-Metabolic (CKM) syndrome (stages 0–3) experience a notably higher incidence of CVD. Previous research has indicated a potential link between the estimated glucose disposal rate (eGDR) and the development of CVD; however, this association within the context of CKM syndrome stages 0–3 remains inadequately explored.

Methods and results

The study comprised 5,286 participants, with an average age of 58 years (range: 52–65 years), including 46.86 % males. The study employed information from the CHARLS dataset to analyze the eGDR, calculated using parameters such as glycated hemoglobin levels, blood pressure, and waist circumference (WC). CVD diagnoses were identified through standardized questionnaires. To investigate the link eGDR-CVD risk across CKM syndrome stages 0–3, we applied a Cox proportional hazards model. Additionally, we assessed the nonlinear relationship through smooth curve fitting and threshold effect analysis. The Cox model indicated that individuals with the highest eGDR experienced a 44 % reduction in CVD risk compared to those with the lowest eGDR. Smooth curve fitting displayed an L-shaped trend, revealing a critical threshold at 11.46 mg/kg/min. This threshold can help clinicians identify individuals at higher CVD risk and guide more intensive prevention strategies.

Conclusion

Our findings reveal a significant inverse relationship eGDR-CVD risk among patients with CKM syndrome stages 0–3. This association exhibited a non-linear, L-shaped pattern, with a crucial threshold identified at 11.46 mg/kg/min.

背景与目的：代谢过程、肾脏健康和心血管疾病（CVD）之间的复杂关系越来越引起人们的兴趣。处于心血管-肾-代谢综合征（CKM）早期阶段（0-3期）的个体CVD的发病率明显较高。先前的研究表明，估计的葡萄糖处置率（eGDR）与心血管疾病的发展之间存在潜在的联系；然而，在CKM综合征0-3期的背景下，这种关联仍然没有得到充分的探讨。方法与结果：研究纳入5286名参与者，平均年龄58岁（范围：52-65岁），其中46.86%为男性。该研究使用CHARLS数据集的信息来分析eGDR，使用糖化血红蛋白水平、血压和腰围（WC）等参数计算。通过标准化问卷确定CVD诊断。为了研究eGDR-CVD风险在CKM综合征0-3期之间的联系，我们应用了Cox比例风险模型。此外，我们通过平滑曲线拟合和阈值效应分析来评估非线性关系。Cox模型表明，与eGDR最低的人相比，eGDR最高的人患心血管疾病的风险降低了44%。平滑曲线拟合呈l型趋势，临界阈值为11.46 mg/kg/min。这个阈值可以帮助临床医生识别心血管疾病风险较高的个体，并指导更密集的预防策略。结论：我们的研究结果显示，在CKM综合征0-3期患者中，eGDR-CVD风险呈显著负相关。这种关联呈现非线性的l型模式，关键阈值为11.46 mg/kg/min。

{"title":"Association between estimated glucose disposal rate and incidence of cardiovascular diseases in a population with cardiovascular-kidney-metabolic syndrome stages 0–3: A large prospective cohort study","authors":"Yaohua Hu, Xinyang Li, Jian Li, Mengyuan Yu, Xu Li, Wenpeng Cui","doi":"10.1016/j.numecd.2025.104469","DOIUrl":"10.1016/j.numecd.2025.104469","url":null,"abstract":"<div><h3>Background and aim</h3><div>There is growing interest in the intricate relationships among metabolic processes, renal health, and cardiovascular disease (CVD). Individuals in the early stages of Cardiovascular-Kidney-Metabolic (CKM) syndrome (stages 0–3) experience a notably higher incidence of CVD. Previous research has indicated a potential link between the estimated glucose disposal rate (eGDR) and the development of CVD; however, this association within the context of CKM syndrome stages 0–3 remains inadequately explored.</div></div><div><h3>Methods and results</h3><div>The study comprised 5,286 participants, with an average age of 58 years (range: 52–65 years), including 46.86 % males. The study employed information from the CHARLS dataset to analyze the eGDR, calculated using parameters such as glycated hemoglobin levels, blood pressure, and waist circumference (WC). CVD diagnoses were identified through standardized questionnaires. To investigate the link eGDR-CVD risk across CKM syndrome stages 0–3, we applied a Cox proportional hazards model. Additionally, we assessed the nonlinear relationship through smooth curve fitting and threshold effect analysis. The Cox model indicated that individuals with the highest eGDR experienced a 44 % reduction in CVD risk compared to those with the lowest eGDR. Smooth curve fitting displayed an L-shaped trend, revealing a critical threshold at 11.46 mg/kg/min. This threshold can help clinicians identify individuals at higher CVD risk and guide more intensive prevention strategies.</div></div><div><h3>Conclusion</h3><div>Our findings reveal a significant inverse relationship eGDR-CVD risk among patients with CKM syndrome stages 0–3. This association exhibited a non-linear, L-shaped pattern, with a crucial threshold identified at 11.46 mg/kg/min.</div></div>","PeriodicalId":49722,"journal":{"name":"Nutrition Metabolism and Cardiovascular Diseases","volume":"36 3","pages":"Article 104469"},"PeriodicalIF":3.7,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the Editor: Statin-associated myopathy risk in people with HIV-1 infection 致编辑的信：他汀类药物相关肌病在HIV-1感染者中的风险。

IF 3.7 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Nutrition Metabolism and Cardiovascular Diseases

Pub Date : 2025-11-13 DOI: 10.1016/j.numecd.2025.104460

Muhammad Mohid Haroon

引用次数: 0

Reply letter to “Statin-associated myopathy risk in people with HIV-1 infection” 回复“HIV-1感染者他汀类药物相关肌病风险”。

IF 3.7 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Nutrition Metabolism and Cardiovascular Diseases

Pub Date : 2025-11-13 DOI: 10.1016/j.numecd.2025.104461

Gianluca Gazzaniga , Daniele Pastori , Ivano Mezzaroma

引用次数: 0